zuberitamab + orelabrutinib

Zuberitamab + orelabrutinib is a combination therapy comprising a CD20-targeting monoclonal antibody and a selective Bruton's tyrosine kinase (BTK) inhibitor. Zuberitamab is a recombinant human-mouse chimeric anti-CD20 monoclonal antibody that induces B-cell depletion through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Orelabrutinib is a highly selective, irreversible BTK inhibitor designed to minimize off-target activity against other kinases such as ITK, EGFR, and JAK3. This combination is primarily being investigated for the treatment of B-cell malignancies, specifically the MCD subtype of diffuse large B-cell lymphoma (DLBCL), which is characterized by MYD88 and CD79B mutations and is known to be sensitive to BTK inhibition. The integration of these agents aims to enhance therapeutic efficacy by simultaneously targeting B-cell surface antigens and intracellular signaling pathways essential for malignant B-cell survival.

Brand names

AnruizeOrelab

Other names

zuberitamaborelabrutinib